Compare Albertsons Companies Inc (ACI) vs Amgen, Inc. (AMGN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Albertsons Companies Inc vs Amgen, Inc. — how do they compare? Albertsons Companies Inc trades at $12.06 (market cap $5.95B), while Amgen, Inc. trades at $414.1 (market cap $224.14B). The key difference: Amgen, Inc. is far larger — about 37.7× Albertsons Companies Inc's market cap, and Albertsons Companies Inc pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| ACI | AMGN | |
|---|---|---|
Market Cap | $5.95B | $224.14B |
Sector | Consumer Staples | Health |
52-Week High | $19.74 | $417.20 |
52-Week Low | $11.03 | $271.18 |
Enterprise Value | $21.35B | $267.45B |
Dividend Yield | 5.55% | 2.43% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Albertsons (ACI) trades at $12.13, up 1.0% on the day, but remains near multi-year lows after a sharp 22% drop following Q2 2026 earnings miss and lowered guidance. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $80.39B in 2025, but net income margin compressed to 0.08%, reflecting margin pressure. Recent news highlights CEO and CFO stock purchases, AI initiatives like the Safeway ChatGPT plugin, and ongoing shareholder litigation investigations.
The outlook is cautious; ACI presents a deep-value case with low P/S of 0.08, but execution risks and weak profitability trends pose challenges. Analyst consensus is mixed with a $13.20 price target. Key risks include competitive grocery margins, litigation overhangs, and macroeconomic headwinds affecting consumer spending.
Amgen (AMGN) trades at $417.20, up 1.52% with strong technical momentum as price approaches resistance near $421. The company demonstrates robust fundamentals with Q2 2026 EPS beating estimates at $6.29 versus $5.62 expected, marking the third consecutive quarterly beat. Revenue growth continues with 2025 revenue reaching $36.75 billion and 2026 projected at $38.1 billion, supported by strong performance from key products like Tezspire and Repatha.
Amgen presents a compelling growth story with raised 2026 guidance and strong product pipeline, though elevated valuation ratios (P/E 25.73, P/S 5.91) and high debt levels ($56.55 billion long-term debt) warrant caution. Analyst consensus remains bullish with 59% buy ratings and $394.69 price target, but current price trades above consensus target, suggesting near-term consolidation potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Albertsons Companies Inc
Albertsons is the second-largest traditional grocer in America, operating 2,276 stores under 24 banners in 34 states (as of the end of fiscal 2021). Around 75% of stores have pharmacies, while nearly 20% also sell fuel. Albertsons has a significant private-label operation, accounting for around 20% of sales (excluding fuel). While its own brand assortment is mainly manufactured by third parties, Albertsons operates 20 food production plants (as of the end of fiscal 2021). Albertsons is a top-two grocer in two thirds of its major markets (as of early 2022, according to company data), and virtually all of its sales come from the United States.
Read more on ACI →About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →
